Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000, C546S118000, C514S303000
Reexamination Certificate
active
07135482
ABSTRACT:
Bicyclic hydroxamate compounds represented by the Formula I:are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
REFERENCES:
patent: 5616609 (1997-04-01), Ikekawa et al.
patent: 5726203 (1998-03-01), Li et al.
patent: 6395743 (2002-05-01), Heimbuch et al.
patent: 6403347 (2002-06-01), Bills et al.
patent: 2002/0123527 (2002-09-01), Walker et al.
patent: 1 375 486 (2004-01-01), None
patent: 2 271 566 (1994-04-01), None
patent: 2 306 476 (1997-05-01), None
patent: 2 327 674 (1999-02-01), None
patent: WO 98/18473 (1998-05-01), None
patent: WO 00/68235 (2000-11-01), None
patent: WO 01/09114 (2001-02-01), None
patent: WO 02/02516 (2002-01-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/077850 (2003-09-01), None
patent: WO 03/082881 (2003-10-01), None
patent: WO 03/086319 (2003-10-01), None
patent: WO 02/070491 (2003-12-01), None
patent: WO 2004/039803 (2004-05-01), None
patent: WO 2004/067531 (2004-08-01), None
U.S. Appl. No. 60/422,513, filed Oct. 31, 2002, Michael Bruno Plewe, et al.
Abdel-Magid, A.F., et al., “Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride,”Tetrahedron Letters, 1990, 5595-5598, vol. 31, No. 39.
Abdel-Magid, et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride,”Journal of Organic Chemistry, 1996, 3849-3862, vol. 61.
Bagshawe, K., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug Development Research, 1995, 220-230, vol. 34.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immonsuppresive Drug,”Journal of Medicinal Chemistry, 1997, 2011-2016, vol. 40.
Biere, H., et al., “Ein einfacher Zugang zum Pyrrol[1,2-c]pyrimidin und Pyrrolo[3,2-c]pyridin-System,”Liebigs Ann. Chem., 1987, 491-497.
Blatt, A. H., et al.,Organic, Synthesis, Collectivevol. 2., 1943, 67, vol. 2, John Wiley & Sons, New York.
Bodor, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research, 1984, 255-331, vol. 13.
Brewster, J., et al., “Carbon-Carbon Alkylations with Amines and Ammonium Salts,”Organic Reactions, vol. VII, 1953, 99-197, vol. 7.
Bundgaard,Design of Prodrugs, 1985, Elsevier Press, New York.
Butler, S.L., et al., “A quantitative assay for HIV DNA integrationin vivo,” Nature Medicine, May 2001, 631-634, vol. 7, No. 5.
Cain, M., et al., “Biomimetic Approach to Potential Benzodiazepine Agonists and Antagonists,”Heterocycles, 1982, 1003-1007, vol. 19, No. 6.
Chen, B.K., et al., “Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses,”Journal of Virology, 1994, 654-660, vol. 68, No. 2.
Chen, et al., “Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding,”PNAS, 2000, 8233-8238, vol. 97, No. 15.
Coker, J.N., et al., “The Cyanomethylation of Indole,”Journal of Organic Chemistry, 1963, 589-590, vol. 28.
Dear, et al., “Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography—mass spectrometry—nuclear magnetic resonance spectroscopy,”Journal of Chromatography B, 2000, 281-293. vol. 748.
Debyser, Z., et al., “Assays for the Evaluation of HIV-1 Integrase Inhibitors,”Methods in Molecular Biology, 2001, 139-155, vol. 160, Schein, C.H. (ed.), Humana Press, Inc., Totawa, NJ.
Dekhane, M., et al., “A Practical Synthesis of 1h-Pyroolo[2,3-c]Pyridine-5-Carboxylic Acid Derivatives From Pyrrole-2-Carboxaldehydes,”Tetrahedron, 1993, 8139-8146, vol. 49, No. 36.
Dodd, R.H., et al., “The Oxidation of Aromatic Aldehydes to Carboxylic Acids Using Hydrogen Peroxide in Formic Acid,”Synthesis, 1993, 295-297.
Dodd, R.H., et al., “Synthesis and Pharmacological Activity of a Pyrido [3′, 4′:5,4]Pyrrolo[1,2-c]-c[1,4] Benzodiazepine-3, 10-Dione, A New Benzodiazepine-β-Carboline Type Hybrid Molecule,”Heterocycles, 1989, 1101-1113, vol. 28, No. 2.
Doisy, X., et al., “Synthesis and Benzodiazepine Receptor (ω Receptor) Affinities of 3-Substituted Derivatives of Pyrrolo[2,3-c]pyridine-5-Carboxylate, a Novel Class ω1Selective Ligands,”Bioorganic Medicinal Chemistry, 1999, 921-932, vol. 7.
Eberle, M.K., “Contribution to the Chemistry of Indole About the 5-(1-Indolyl)-2-pentanone System,”Journal of Organic Chemistry, 1976, 633-636, vol. 41, No. 4.
Gilchrist, T.L., et al., “Synthesis of Fused Pyridines under Neutral Conditions,”J.C.S. Chem. Comm., 1979, 627-628.
Goldgur, Y., et al., “Structure of the HIV-1 Integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design,” PNAS, Nov. 1999, 13040-13043, vol. 96, No. 23.
Greene, T.W., “Protective Groups in Organic Chemistry” 3rdEdition, 1999, 531-537, John Wiley & Sons.
Grobler, J., et al., “Diketo Acid Inhibitor Mechanism and HIV-1 Integrase: Implications for Metal Binding in the Active Site of Phosphotransferase Enzymes,”PNAS, 2002, 6661-6666, vol. 99, No. 10.
Guzman, F., et al., “Biomimetic Approach to Potential Benzodiazepine Receptor Agonists and Antagonists,”Journal of Medicinal Chemistry, 1984, 564-570, vol. 27.
Hansen, M. S., et al., “Integration complexes derived from HIV vectors for rapid assays in vitro,”Nature Biotechnology, Jun. 1999, 578-582, vol. 17, No. 6.
Hazuda, D., et al., “Discovery and Analysis of Inhibitors of the Human Immunodeficiency Integrase,”Drug Design and Discovery, 1997, 17-24, vol. 15.
Henn, L., et al., “Formation of Indoles, Isoquinolines, and Other Fused Pyridines from Azidocrylates,”J. Chem. Soc. Perkin. Trans., 1984, 2189-2196, vol. 1.
Hughes, D., “Progress in the Mitsunobu Reaction. A Review,”Org. Prep. Proced. Int., 1996, 127-164, vol. 28.
Jenkins, T.M., et al., “A Soluble Active Mutant of HIV-1 Integrase,”Journal of Biological Chemistry, 1996, 7712-7718, vol. 271, vol. 13.
Kantlehner, W., et al., “Umsetzungen vontert-Butoxy-N,N,N1,N1-tetramethylmethandiamin mit NH- und CH-aciden Verbingdungen,”Liebigs Ann. Chem., 1980, 344-357.
Kelley, J.L., et al., “Attempted Inhibition of Histidine Decarboxylase with β-Alkyl Analogues of Histidine,”Journal of Medicinal Chemistry, 1977, 721-723, vol. 20, No. 5.
Kozikowski, A. P., et al., “Use of N,N-Dimethyl(Methylene)Ammonium Chloride in the Functionalization of Indoles,”Heterocycles, 1980, 55-58, vol. 14, No. 1.
Kreher, R. P., et al., “Cyclisierende Kondesation von 1H—Pyrrol-3,4-dicarbaldeyden mit 1,2-bifunktionellen Verbindugen [1],”Chemiker-Zeitung, 1984, 275-277, vol. 108, No. 9.
Krutosikova, A., et al., “Condensed O-, N-Heterocycles by the Transformation of Azidoacrylates,”Monatsh. Chem., 1992, 807-815, vol. 123.
Lane, C. F., “Sodium Cynanoborohydride—A Highly Selective Reducing Agent for Organic Functional Groups,”Synthesis, 1975, 135-146.
Larsen, “Design and Application of Prodrugs.”Drug Design and Development, 1991, Krogsgaard-Larsen et al., Eds., Harwood Academic Publishers, Chur, Switzerland.
Lee, J.G., et al., “Aromatization of Cyclohexenes and Cyclohexadienes With Selenium Dioxide-Trimethylsilyl Polyphosphate,”Tetrahedron Letters, 1992, 6363-6366, vol. 33, No. 42.
Lewin, S.R., et al., “Use of Real-Time PCR and Molecular Beacons to Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Anti
Hu Qiyue
Johnson Ted William
Kuki Atsuo
Nowlin Dawn Marie
Plewe Michael Bruno
Agouron Pharmaceuticals , Inc.
Owens Amelia A.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
HIV-integrase inhibitors, pharmaceutical compositions, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-integrase inhibitors, pharmaceutical compositions, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-integrase inhibitors, pharmaceutical compositions, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3650197